Morningstar | McKesson Reports Solid Quarterly Results With Steady Top-Line Core Drug Distribution Growth
McKesson reported third-quarter (fiscal-year 2019) results largely in line with our expectations and ahead of consensus projections with steady top-line growth from the core U.S. distribution business. We don't expect to make any major changes to our fair value estimate or moat rating based on the results.McKesson's core U.S. drug distribution business posted top-line gains of 6%, but profit slightly fell as we believe pricing pressures weighed on the division. Longer term, a key growth driver for the firm and the other major drug wholesalers will be their ability to offset the growing strength of smaller pharmacies that are banding together to force more pricing discounts. McKesson's strong positioning in the drug supply channel should enable the firm to stabilize pricing with these smaller pharmacy groups as well as the larger pharmacies.
Outside the drug distribution business, the company's medical surgical solutions business posted 19% sales growth, aided by both market growth and an acquisition. Further, profits looked solid in this segment, increasing slightly faster than the top line. While this division is outside McKesson's core operations, the segment does lift overall margins.
Additionally, as announced in late 2018, the company remains on track for longtime CEO John Hammergren to step down in April, and COO Brian Tyler will step into the leadership position. We expect Tyler's over 20 years of experience at McKesson in positions across the company's core divisions will help guide the company through the current dynamic and challenging drug pricing environment.
McKesson provides pharmaceuticals and medical supplies and services to its customers. The company's segments include: U.S. Pharmaceutical and Specialty Solutions, which provides distribution and logistics services for branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs and other healthcare-related products to customers; European Pharmaceutical Solutions, which provides distribution and services to wholesale, institutional and retail customers in European countries where it owns, partners or franchises with retail pharmacies; and Medical-Surgical Solutions, which delivers medical-supply distribution, logistics, biomedical and other services to healthcare providers.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.